[{"orgOrder":0,"company":"Biophta","sponsor":"HTL Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"BO-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biophta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Biophta \/ HTL Biotechnology","highestDevelopmentStatusID":"4","companyTruncated":"Biophta \/ HTL Biotechnology"},{"orgOrder":0,"company":"Biophta","sponsor":"UI Investissement","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"BO-001","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biophta","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Insert","sponsorNew":"Biophta \/ UI Investissement","highestDevelopmentStatusID":"4","companyTruncated":"Biophta \/ UI Investissement"},{"orgOrder":0,"company":"Nicox SA","sponsor":"Glaukos","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Other Small Molecule","year":"2024","type":"Licensing Agreement","leadProduct":"NCX 1728","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Nicox SA","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nicox SA \/ Glaukos","highestDevelopmentStatusID":"4","companyTruncated":"Nicox SA \/ Glaukos"},{"orgOrder":0,"company":"Biophytis","sponsor":"BPI","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Antibody-drug Conjugate","year":"2021","type":"Funding","leadProduct":"Macuneos","moa":"PPA-alpha receptor","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Biophytis","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Biophytis \/ BPI","highestDevelopmentStatusID":"4","companyTruncated":"Biophytis \/ BPI"},{"orgOrder":0,"company":"SparingVision","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Inapplicable","leadProduct":"SPVN06","moa":"RdCVF\/RdCVFL","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"SparingVision","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"SparingVision \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"SparingVision \/ Inapplicable"},{"orgOrder":0,"company":"PulseSight Therapeutics","sponsor":"Pureos Bioventures","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Inapplicable","leadProduct":"PST-809","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"PulseSight Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PulseSight Therapeutics \/ Pureos Bioventures","highestDevelopmentStatusID":"4","companyTruncated":"PulseSight Therapeutics \/ Pureos Bioventures"},{"orgOrder":0,"company":"Variant","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"FRANCE","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"VAR002","moa":"CRX gene","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"Variant","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Subretinal Injection","sponsorNew":"Variant \/ Inapplicable","highestDevelopmentStatusID":"4","companyTruncated":"Variant \/ Inapplicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : VAR002 is a recombinant adeno-associated viral (rAAV) vector initially developed to treat Leber's congenital amaurosis, Retinitis pigmentosa, and Cone-rod dystrophy due to a mutation in the CRX gene.

                          Product Name : VAR002

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          April 03, 2025

                          Lead Product(s) : VAR002

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Under the license agreement, Glaukos will fund and conduct NCX 1728 preclinical research activities evaluating it in glaucoma (including neuroprotection) and other retinal diseases.

                          Product Name : NCX 1728

                          Product Type : Other Small Molecule

                          Upfront Cash : Undisclosed

                          September 23, 2024

                          Lead Product(s) : NCX 1728

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Glaukos

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank

                          03

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The financing aims to fund the first-in-human trial of breakthrough topical ophthalmic investigational product BO-001 for the the treatment of glaucoma.

                          Product Name : BO-001

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 06, 2024

                          Lead Product(s) : BO-001

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : HTL Biotechnology

                          Deal Size : $6.9 million

                          Deal Type : Financing

                          blank

                          04

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : The financing aims to fund the first-in-human trial of breakthrough topical ophthalmic investigational product BO-001 for the the treatment of glaucoma.

                          Product Name : BO-001

                          Product Type : Undisclosed

                          Upfront Cash : Undisclosed

                          March 06, 2024

                          Lead Product(s) : BO-001

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : UI Investissement

                          Deal Size : $6.9 million

                          Deal Type : Financing

                          blank

                          05

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : PST-809, is a potential first-in-class therapy for wet age-related macular degeneration that comprises a dual-gene plasmid encoding for anti-VEGF, aflibercept, together with decorin.

                          Product Name : PST-809

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          February 27, 2024

                          Lead Product(s) : PST-809

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Pureos Bioventures

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          06

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : Macuneos (BIO201) is an orally administered small molecule in development for the treatment of diseases of the retina, or retinopathies. Biophytis has completed preclinical cellular and animal studies of Macuneos (BIO201) for the treatment of retinopathi...

                          Product Name : BIO201

                          Product Type : Antibody-drug Conjugate

                          Upfront Cash : Undisclosed

                          April 29, 2021

                          Lead Product(s) : Macuneos

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : BPI

                          Deal Size : $1.1 million

                          Deal Type : Funding

                          blank

                          07

                          EPS
                          Not Confirmed
                          EPS
                          Not Confirmed

                          Details : SPVN06 uses a gene therapy-based approach independent of mutated genes and by a single subretinal injection of proprietary neurotrophic factors, aims at stopping and preventing the degeneration of photoreceptors leading to blindness.

                          Product Name : SPVN06

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Inapplicable

                          June 30, 2020

                          Lead Product(s) : SPVN06

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank